Intel stock spikes after report of possible US government stake
BOCA RATON, Fla. - Sensus Healthcare, Inc. (NASDAQ:SRTS), a profitable medical device company with a market capitalization of $74 million and healthy financials including a current ratio of 9.64, announced a study’s findings showing the effectiveness of their SRT-100® system in treating keloids. According to InvestingPro data, the company maintains more cash than debt on its balance sheet, indicating strong financial health. Published in the Annals of Plastic Surgery, the research involved 12 patients with 16 keloids treated at Tri Service Military Hospital in Taiwan. The study, which marks Sensus Healthcare’s first in Asia, demonstrated no recurrence of keloids in patients followed for over six months after combining surgical excision with Superficial Radiation Therapy (SRT).
Keloids are benign skin growths that can cause discomfort, itching, and pain, extending beyond the original wound area. Traditional treatments, like corticosteroid injections, cryotherapy, and laser therapy, often result in high recurrence rates. The SRT-100® system aims to reduce this by targeting fibroblast activity that leads to keloid regrowth.
Joe Sardano, CEO of Sensus Healthcare, expressed satisfaction with the study’s results, emphasizing the system’s role in improving patient outcomes. Despite the stock’s recent 28% decline over the past six months, analysts maintain optimistic projections, with InvestingPro showing a consensus recommendation leaning towards "Buy." According to the study, the integration of SRT with surgical excision offers a non-invasive, targeted solution that significantly lowers recurrence rates.
Sensus Healthcare focuses on non-invasive treatments for skin cancer and keloids, utilizing superficial radiotherapy technology to provide patient-centric solutions. The study’s positive outcome reinforces the company’s commitment to advancing therapies that improve the quality of life for those with dermatological conditions, particularly in regions like southeast Asia where keloids are more common.
This press release also includes forward-looking statements regarding Sensus Healthcare’s future performance and market position. These statements are subject to risks and uncertainties that could cause actual results to differ from those projected. With a revenue growth of 71% in the last twelve months and current undervaluation according to InvestingPro analysis, investors seeking detailed insights can access comprehensive Pro Research Reports covering 1,400+ top stocks, including SRTS, transforming complex financial data into actionable intelligence.
The study is available in the March 2025 issue of the Annals of Plastic Surgery. The information reported is based on a press release statement from Sensus Healthcare, Inc.
In other recent news, Sensus Healthcare announced its financial results for the fourth quarter and the full fiscal year of 2024, revealing a notable performance. The company reported a total revenue of $13.1 million for the fourth quarter, exceeding analyst forecasts of $10.0 million, and marking a year-over-year growth of 4%. However, the earnings per share (EPS) fell short of expectations, coming in at $0.09 compared to the anticipated $0.11. For the full year, Sensus Healthcare’s revenue surged by 71% to $41.8 million, surpassing projections of $38.8 million, with a net income of $6.6 million, or $0.41 per share.
H.C. Wainwright analyst Raghuram Selvaraju responded to these financial disclosures by raising the price target for Sensus Healthcare shares to $12.00 from the previous $11.00, while maintaining a Buy rating on the stock. This adjustment reflects the company’s strong financial performance and promising growth prospects. Sensus Healthcare’s expansion efforts included setting a new quarterly record by shipping 39 SRT systems in the fourth quarter, with a total of 115 systems shipped throughout 2024, surpassing the expected 100 systems.
The company also highlighted the signing of additional Fair Deal Agreement revenue-sharing programs, which are expected to contribute significantly to its top-line growth in the coming year. An interesting development was the sale of an SRT system to a veterinary clinic, indicating potential in the companion animal health market. Looking ahead, Sensus Healthcare plans to resubmit its TDI-510 application in the first half of 2025, potentially enhancing its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.